Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice

International Journal of Pharmaceutics

Volumn 293, Issue 1-2, 2005, Pages 281-290

  Bibby, David C ^a   Talmadge, James E ^b   Dalal, Milind K ^a   Kurz, Scott G ^b   Chytil, Kevin M ^b   Barry, Stephen E ^a   Shand, David G ^a   Steiert, Matthias ^a  

^a Alnis BioSciences Inc   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Biodistribution; Doxorubicin; Mice; Nanoparticles; Pharmacokinetics

Indexed keywords

AMIDE; ARGINYLGLYCYLASPARTIC ACID; CYCLOPEPTIDE; DOXORUBICIN; INULIN; MACROGOL 400; METHACRYLIC ACID DERIVATIVE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG ACCUMULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEART; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUMOR;

EID: 15044353995     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.12.021     Document Type: Article

References (23)

1. V. Devita, S. Hellman, and S. Rosenberg Cancer, Principles and Practice of Oncology third ed. 1989 Lippincott Philadelphia 376 pp.
2. D.L. Dexter, H.M. Kowalski, B.A. Blazar, Z. Fligiel, R. Vogel, and G.H. Heppner Heterogeneity of tumor cells from a single mouse mammary tumor Cancer Res. 38 1978 3174 3181
3. R. Duncan, J.K. Coatsworth, and S. Burtles Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1) Hum. Exp. Toxicol. 17 1998 93 104
4. J.R. Griffiths Are cancer cells acidic? Br. J. Cancer 64 1991 425 427
5. D.L. Gustafson, J.C. Rastatter, T. Colombo, and M.E. Long Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model J. Pharm. Sci. 91 2002 1488 1501
6. L. Harris, G. Batist, R. Belt, D. Rovira, R. Navari, N. Azarnia, L. Welles, and E. Winer Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 2002 25 36
7. R.L. Hong, C.J. Huang, Y.L. Tseng, V.F. Pang, S.T. Chen, J.J. Liu, and F.H. Chang Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin. Cancer Res. 5 1999 3645 3652
8. J. Kopeček, P. Kopečková, T. Minko, and Z.-R. Lu HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action Eur. J. Pharm. Biopharm. 50 2000 61 81 (review)
9. M. Kovar, T. Mrkvan, J. Strohalm, T. Etrych, K. Ulbrich, M. Stastny, and B. Rihova HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia J. Control Release 92 2003 315 330
10. J. Kuiper, H.F. Bakkeren, E.A.L. Bissen, and T.J.C. Van Berkel Characterization of the interaction of galactose-exposing particles with rat kupffer cells Biochem. J. 299 1994 285 290
11. G.S. Kwon Polymeric micelles for delivery of poorly water soluble compounds Crit. Rev. Ther. Drug Carrier Syst. 20 2003 357 403
12. G. Kwon, S. Suwa, M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugates J. Control Release 29 1994 17 23
13. Martindale Royal Pharmaceutical Society London 31st ed. 1996 Pharmaceutical Press London 567 pp.
14. F.R. Miller, B.E. Miller, and G.H. Heppner Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability Invasion Metastasis 3 1983 22 31
15. R. Pasqualini, E. Koivunen, and E. Ruoslahti Alpha v integrins as receptors for tumor targeting by circulating ligands Nat. Biotechnol. 15 1997 542 546
16. R.M. Schiffelers, G.A. Koning, T.L. ten Hagen, M.H. Fens, A.J. Schraa, A.P. Janssen, R.J. Kok, G. Molema, and G. Storm Antitumor efficacy of tumor vasculature-targeted liposomal doxorubicin J. Control Release 91 2003 115 122
17. L.W. Seymour, K. Ulbrich, J. Strohalm, J. Kopeček, and R. Duncan The pharmacokinetics of polymer-bound adriamycin Biochem. Pharmacol. 39 1990 1125 1131
18. J.E. Talmadge, I.J. Fidler, and R.K. Oldham Screening for biological response modifiers: methods and rationale 1985 Martinus Nijhoff The Hague
19. I.F. Tannock, and D. Rotin Acid pH in tumors and its potential for therapeutic exploitation Cancer Res. 49 1989 4373 4384
20. K. Ulbrich, T. Etrych, P. Chytil, M. Jelinkova, and B. Rihova HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity J. Control Release 87 2003 33 47
21. J. Van Asperen, O. Van Tellingen, and J.H. Beijnen Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography J. Chromatog. B 712 1998 129 143
22. J.B. Vermorken The role of anthracyclines in second-line therapy of ovarian cancer Int. J. Gynecol. Cancer 13 Suppl. 2 2003 178 184
23. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis Jr., A.L. Von Hoff, M. Rozencweig, and F.M. Muggia Risk factors for doxorubicin-induced congestive heart failure Ann. Intern. Med. 91 1979 710 717